Fondaparinux Sodium
- PDF / 161,066 Bytes
- 13 Pages / 592.44 x 751.18 pts Page_size
- 14 Downloads / 145 Views
Am J Cardiovasc Drugs 2008; 8 (2): 113-125 1175-3277/08/0002-0113/$48.00/0 © 2008 Adis Data Information BV. All rights reserved.
Fondaparinux Sodium A Review of its Use in the Management of Acute Coronary Syndromes Stephanie K.A. Blick, Jennifer S. Orman, Antona J. Wagstaff and Lesley J. Scott Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA Various sections of the manuscript reviewed by: B. Bhargava, Cardiothoracic Sciences Centre, All India Institute of Medical Sciences, New Delhi, India; J.J. Ferguson, Texas Heart Institute, The University of Texas Health Science Center at Houston, Houston, Texas, USA; A. Gallus, Department of Haematology, Flinders Medical Centre and Flinders University, Adelaide, South Australia, Australia; R. Giugliano, Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts, USA; S.R. Mehta, Division of Cardiology, McMaster University, Hamilton, Ontario, Canada; J. Weitz, Division of Cardiology, McMaster University, Hamilton, Ontario, Canada.
Data Selection Sources: Medical literature published in any language since 1980 on ‘fondaparinux sodium’, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Wolters Kluwer Health | Adis). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: MEDLINE, EMBASE and AdisBase search terms were ‘fondaparinux’ and ‘coronary’ or ‘acute coronary syndromes’ or ‘Oasis’. Searches were last updated 28 March 2008. Selection: Studies in patients with acute coronary syndromes who received fondaparinux. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included. Index terms: Fondaparinux sodium, acute coronary syndromes, ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, unstable angina pectoris, pharmacodynamics, pharmacokinetics, therapeutic use, pharmacoeconomics, tolerability.
Contents Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114 1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115 2. Pharmacodynamic Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115 3. Pharmacokinetic Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Data Loading...
